Biofrontera Inc. Form 8-K Summary
Business Context and Reporting Period
Biofrontera Inc. filed a Form 8-K dated May 30, 2023, under Item 4.01 regarding a change in its independent registered public accounting firm. The report references fiscal years ended December 31, 2022 and 2021 and the subsequent interim period through May 30, 2023. The filing was signed June 2, 2023.
Financial Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating performance metrics.
Material Changes
- Grant Thornton LLP resigned as Biofrontera’s independent registered public accounting firm effective May 30, 2023.
- Grant Thornton’s audit reports on the Company’s consolidated financial statements for the years ended December 31, 2022 and 2021 contained no adverse opinion or disclaimer and were not qualified or modified.
- The Company stated that there were no accounting or auditing disagreements with Grant Thornton during the stated periods.
- The Company stated that there were no reportable events, except for a material weakness in internal control over financial reporting related to management’s review of work performed by specialists as of December 31, 2021.
- Biofrontera had not engaged a replacement independent registered public accounting firm as of the filing.
Outlook, Risks, and Unusual Items
The auditor transition may create execution, timing, and reporting risks until a replacement firm is appointed. Investors should also consider the disclosed material weakness involving management’s review of specialist work. The filing does not provide management guidance or an updated financial outlook.
Important Facts to Verify
- Whether Grant Thornton’s resignation affected the timing or scope of future audits or SEC filings.
- When Biofrontera appoints a new independent registered public accounting firm.
- Whether the previously disclosed material weakness has been remediated or remains outstanding.
- The contents of Grant Thornton’s June 2, 2023 letter filed as Exhibit 16.1.